GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (NAS:CRMD) » Definitions » Shiller PE Ratio

Cormedix (Cormedix) Shiller PE Ratio : (As of May. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cormedix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cormedix Shiller PE Ratio Historical Data

The historical data trend for Cormedix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Shiller PE Ratio Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cormedix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cormedix's Shiller PE Ratio

For the Biotechnology subindustry, Cormedix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cormedix's Shiller PE Ratio falls into.



Cormedix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cormedix's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cormedix's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.25/131.7762*131.7762
=-0.250

Current CPI (Mar. 2024) = 131.7762.

Cormedix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.250 100.560 -0.328
201409 -1.150 100.428 -1.509
201412 -0.450 99.070 -0.599
201503 -1.150 99.621 -1.521
201506 -0.650 100.684 -0.851
201509 -0.700 100.392 -0.919
201512 -0.500 99.792 -0.660
201603 -0.550 100.470 -0.721
201606 -0.650 101.688 -0.842
201609 -1.150 101.861 -1.488
201612 -0.800 101.863 -1.035
201703 -0.950 102.862 -1.217
201706 -0.500 103.349 -0.638
201709 -0.850 104.136 -1.076
201712 -0.750 104.011 -0.950
201803 -0.680 105.290 -0.851
201806 -0.520 106.317 -0.645
201809 -0.540 106.507 -0.668
201812 0.100 105.998 0.124
201903 -0.220 107.251 -0.270
201906 -0.030 108.070 -0.037
201909 -1.350 108.329 -1.642
201912 -0.210 108.420 -0.255
202003 -0.210 108.902 -0.254
202006 -0.140 108.767 -0.170
202009 -0.220 109.815 -0.264
202012 -0.190 109.897 -0.228
202103 -0.200 111.754 -0.236
202106 -0.120 114.631 -0.138
202109 -0.220 115.734 -0.250
202112 -0.200 117.630 -0.224
202203 -0.180 121.301 -0.196
202206 -0.190 125.017 -0.200
202209 -0.170 125.227 -0.179
202212 -0.200 125.222 -0.210
202303 -0.240 127.348 -0.248
202306 -0.250 128.729 -0.256
202309 -0.170 129.860 -0.173
202312 -0.260 129.419 -0.265
202403 -0.250 131.776 -0.250

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cormedix  (NAS:CRMD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cormedix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cormedix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (Cormedix) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.
Executives
Alan W Dunton director VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Erin Mistry officer: Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Joseph Todisco director, officer: Chief Executive Officer 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Myron Kaplan director C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176
Paulo F Costa director MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Robert A Stewart director 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960
Janet Dillione director ONE WAYSIDE ROAD, BURLINGTON MA 01803
Matthew T David officer: EVP, Chief Financial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Elizabeth Masson officer: EVP, Head of Clinical Ops. 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922
Thomas Nusbickel officer: EVP, Chief Commercial Officer 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922
Gregory Scott Duncan director 44 MILTON AVENUE, ALPHARETTA GA 30009
Steven W Lefkowitz director SIX HARRISON STREET, NEW YORK NY 10013
Mehmood Khan director 700 ANDERSON HILL ROAD, PURCHASE NY 10577
Armstrong Jr. John L. officer: Exec VP of Tech Operations C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Khoso Baluch director, officer: Chief Executive Officer 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921